Condition: Multiple Myeloma · Secondary Immunodeficiency (SID) · Sponsor: Takeda
In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice. The study's main aim is to look into infusion parameters of HyQvia administration.
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| Instituto Privado de Investigaciones Clinicas de Cordoba | Córdoba, Argentina | Withdrawn |
| Fakultni nemocnice Plzen | Pilsen, Czechia | Recruiting |
| Vseobecna fakultni Nemocnice | Prague, Czechia | Not Yet Recruiting |
| CHU Amiens - Hopital Sud | Salouël, Somme, France | Recruiting |
| CHU Dijon - Hopital du Bocage | Dijon, France | Not Yet Recruiting |
| Hopital Prive du Confluent | Nantes, France | Recruiting |
| Hopital de la Source - CHR Orleans | Orléans, France | Not Yet Recruiting |
| CHU Bordeaux - Hopital Haut-Leveque | Pessac, France | Not Yet Recruiting |
| MHP-Muenchner Haematologiepraxis | Berlin, Germany | Not Yet Recruiting |
| Alexandra General Hospital | Athens, Greece | Recruiting |
| General Hospital of Thessaloniki "G. Papanikolaou" | Thessaloniki, Greece | Recruiting |
| A.O.U.C Policlinico di Bari | Bari, Italy | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05879757